ATE445164T1 - Zusammensetzungen und methoden zum nachweis, behandeln oder vorhersagen der antwort von brust tumorzellen auf eine endocrin-therapie - Google Patents

Zusammensetzungen und methoden zum nachweis, behandeln oder vorhersagen der antwort von brust tumorzellen auf eine endocrin-therapie

Info

Publication number
ATE445164T1
ATE445164T1 AT00401778T AT00401778T ATE445164T1 AT E445164 T1 ATE445164 T1 AT E445164T1 AT 00401778 T AT00401778 T AT 00401778T AT 00401778 T AT00401778 T AT 00401778T AT E445164 T1 ATE445164 T1 AT E445164T1
Authority
AT
Austria
Prior art keywords
compositions
methods
treating
tumor cells
detecting
Prior art date
Application number
AT00401778T
Other languages
English (en)
Inventor
Michel Vidaud
Ivan Bieche
Original Assignee
Univ Paris Descartes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Paris Descartes filed Critical Univ Paris Descartes
Application granted granted Critical
Publication of ATE445164T1 publication Critical patent/ATE445164T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575Hormones
    • G01N2333/59Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT00401778T 2000-06-22 2000-06-22 Zusammensetzungen und methoden zum nachweis, behandeln oder vorhersagen der antwort von brust tumorzellen auf eine endocrin-therapie ATE445164T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00401778A EP1167975B1 (de) 2000-06-22 2000-06-22 Zusammensetzungen und Methoden zum Nachweis, Behandeln oder Vorhersagen der Antwort von Brust Tumorzellen auf eine Endocrin-Therapie

Publications (1)

Publication Number Publication Date
ATE445164T1 true ATE445164T1 (de) 2009-10-15

Family

ID=8173738

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00401778T ATE445164T1 (de) 2000-06-22 2000-06-22 Zusammensetzungen und methoden zum nachweis, behandeln oder vorhersagen der antwort von brust tumorzellen auf eine endocrin-therapie

Country Status (3)

Country Link
EP (1) EP1167975B1 (de)
AT (1) ATE445164T1 (de)
DE (1) DE60043100D1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE437962T1 (de) * 2002-10-01 2009-08-15 Epigenomics Ag Verfahren für die behandlung von proliferativen erkrankungen von brustzellen
ES2609234T3 (es) * 2003-06-24 2017-04-19 Genomic Health, Inc. Predicción de la probabilidad de recidiva de cáncer
WO2008133493A1 (en) * 2007-04-27 2008-11-06 Erasmus University Medical Center Rotterdam Prediction of responsiveness to anti-estrogen treatment in breast cancer
EP2932272A4 (de) * 2012-10-17 2016-09-14 Ma Runlin Z Shon als prognostischer biomarker für krebs und als prädiktor der reaktion auf eine endokrintherapie
CN114045336B (zh) * 2021-09-28 2024-01-02 中国人民解放军空军军医大学 Cga基因作为靶点在制备用于诊断和治疗耐药实体瘤药物的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9608143D0 (en) * 1996-04-19 1996-06-26 Ver Nl Kanker Inst Assay
US5997871A (en) * 1996-06-24 1999-12-07 University Of Maryland Biotechnology Insitute Treatment and prevention of cancer by administration of derivatives of human chorionic gonadotropin

Also Published As

Publication number Publication date
EP1167975A1 (de) 2002-01-02
DE60043100D1 (de) 2009-11-19
EP1167975B1 (de) 2009-10-07

Similar Documents

Publication Publication Date Title
BRPI0315666B8 (pt) dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos
IL149922A (en) Tweak receptor antagonist for use in regulating the angiogenesis process, a nucleic acid encoded by the antagonist, expression and host cells that contain the expression carrier and the antagonist to produce the antagonist
DE60130797D1 (de) Verwendung von spezifischen erbb4 antagonisten zur behandlung von stenose
ATE396266T1 (de) Trp8 krebsmarker
DK0961780T3 (da) Proteinmarkörer for lungecancer og anvendelse deraf
DK0917571T3 (da) Hidtil ukendt agoutirelateret gen
PT1548032E (pt) Péptidos kdr e vacinas que os contêm
NO20000752L (no) Metode for forhindring eller behandling av østrogen-avhengige sykdommer og forstyrrelser
ATE292801T1 (de) Verfahren zum screening von inhibitoren von asp2
BRPI0418229A (pt) genes do ciclo celular e métodos corrrelatos de uso
ATE445164T1 (de) Zusammensetzungen und methoden zum nachweis, behandeln oder vorhersagen der antwort von brust tumorzellen auf eine endocrin-therapie
AU2003293141A8 (en) Methods for identifying risk of breast cancer and treatments thereof
ATE485059T1 (de) Tumortherapie mit vektoren auf sindbis virus- basis
DE69943129D1 (de) Identifikation des gens das zum schorfigen phenotyp der maus führt, sowie seines menschlichen orthologs
NO20002412L (no) FremgangsmÕte for behandling av tumorer og tumorceller ved anvendelse av ex vivo aktiverte T celler
NO20040553L (no) BV8 Nukleinsyrer og polypeptider med mitogen aktivitet.
ATE464320T1 (de) Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk)
ATE534902T1 (de) Replikationsproteinn ciz1
WO2002064023A3 (en) Fra-1 expression in brain cancer
DE69734143D1 (de) Neue methoden zur charakterisierung von verbindungen, welche die stf-1 expression in inselzellen der bauchspeicheldrüse stimuliert
ATE466958T1 (de) Klassifizierung von kolonkrebs
EP1507787A4 (de) Mit prostatakrebs in zusammenhang stehende zusammensetzungen, verfahren und kits auf grundlage von dna-makroarray-proteom plattformen
ATE382637T1 (de) Rezeptor-tyrosine-kinase gene
ATE291738T1 (de) Diagnose und behandlung von krebs unter verwendung von sgp28-ähnlichen molekülen
DE602005021159D1 (de) Bakteriophagen- und prophagen-proteine in der krebsgentherapie

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1167975

Country of ref document: EP